Skip to main content

Advertisement

SpringerLink
Log in

The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer summary and research recommendations. J Clin Oncol 28:2114–2122

    Article  PubMed Central  PubMed  Google Scholar 

  2. Nahleh ZA, Srikantiah R, Safa M et al (2007) Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 109:1471–1477

    Article  PubMed  Google Scholar 

  3. Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137:678–687

    Article  PubMed  Google Scholar 

  4. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen inpatients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure toaromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724

    Article  CAS  PubMed  Google Scholar 

  5. Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870–884

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University, Achrafieh, Beirut, Lebanon

    Joseph Kattan & Hampig Raphael Kourie

Authors
  1. Joseph Kattan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hampig Raphael Kourie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hampig Raphael Kourie.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kattan, J., Kourie, H.R. The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. Invest New Drugs 32, 1046–1047 (2014). https://doi.org/10.1007/s10637-014-0133-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-014-0133-2

Keywords

Search

Navigation